Osteoporosis risk assessment and treatment intervention after hip or shoulder fracture - A comparison of two centres in the United Kingdom

被引:50
作者
Murray, AW
McQuillan, C
Kennon, B
Gallacher, SJ
机构
[1] Royal Edinburgh Infirm, Edinburgh EH10 5HF, Midlothian, Scotland
[2] So Gen Hosp, Glasgow G51 4TF, Lanark, Scotland
来源
INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED | 2005年 / 36卷 / 09期
关键词
osteoporosis; fracture prevention; hip fracture; proximal humeral fracture; Bisphosphonates; DEXA; fracture liaison service;
D O I
10.1016/j.injury.2005.03.012
中图分类号
R4 [临床医学];
学科分类号
1002 [临床医学]; 100602 [中西医结合临床];
摘要
This study compares the investigation of and treatment for osteoporosis in two groups of fracture patients at two orthopaedic centres in the UK. One centre had a formal fracture Liaison service (FLS) responsible for screening fracture patients for osteoporosis. The other centre relied upon individual clinicians to initiate investigation or treatment for osteoporosis in patients following fracture. Patients who had been treated in either centre for a proximal humeral or hip fracture during a 6-month period were followed up 6 months Later to identify how many had received screening or treatment for osteoporosis. Information was retrieved from a prospectively compiled database or by postal questionnaire. The study revealed that in the centre with an FLS 85% of patients with a proximal humeral fracture and 20% with a hip fracture had been offered a dual-energy X-ray absorptiometry (DEXA) scan. Approximately 50% and 85%, respectively, were receiving treatment for osteoporosis 6 months following their fracture. This compared with DEXA being offered to only 6% and 9.7% of humeral and hip fracture patients, respectively, and 20% (hip) and 27% (proximal humerus) receiving osteoporosis treatment in the other centre. The presence of an FLS resulted in a considerably higher proportion of patients receiving investigation and treatment for osteoporosis following a hip or proximal humeral fracture. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1080 / 1084
页数:5
相关论文
共 17 条
[1]
[Anonymous], 1997, AM J MED
[2]
VITAMIN-D(3) AND CALCIUM TO PREVENT HIP-FRACTURES IN ELDERLY WOMEN [J].
CHAPUY, MC ;
ARLOT, ME ;
DUBOEUF, F ;
BRUN, J ;
CROUZET, B ;
ARNAUD, S ;
DELMAS, PD ;
MEUNIER, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (23) :1637-1642
[3]
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures - Results from the fracture intervention trial [J].
Cummings, SR ;
Black, DM ;
Thompson, DE ;
Applegate, WB ;
Barrett-Connor, E ;
Musliner, TA ;
Palermo, L ;
Prineas, R ;
Rubin, SM ;
Scott, JC ;
Vogt, T ;
Wallace, R ;
Yates, AJ ;
LaCroix, AZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (24) :2077-2082
[4]
Effect of calcium and vitamin D supplementation on bone, density in men and women 65 years of age or older [J].
DawsonHughes, B ;
Harris, SS ;
Krall, EA ;
Dallal, GE .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (10) :670-676
[5]
Clinical usefulness of risk factors for osteoporosis [J].
Earnshaw, SA ;
Hosking, DJ .
ANNALS OF THE RHEUMATIC DISEASES, 1996, 55 (06) :338-339
[6]
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis - A randomized controlled trial [J].
Harris, ST ;
Watts, NB ;
Genant, HK ;
McKeever, CD ;
Hangartner, T ;
Keller, M ;
Chesnut, CH ;
Brown, J ;
Eriksen, EF ;
Hoseyni, MS ;
Axelrod, DW ;
Miller, PD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (14) :1344-1352
[7]
Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures [J].
Marshall, D ;
Johnell, O ;
Wedel, H .
BRITISH MEDICAL JOURNAL, 1996, 312 (7041) :1254-1259
[8]
The fracture liaison service: success of a program for the evaluation and management of patients with osteoporotic fracture [J].
McLellan, AR ;
Gallacher, SJ ;
Fraser, M ;
McQuillian, C .
OSTEOPOROSIS INTERNATIONAL, 2003, 14 (12) :1028-1034
[9]
MELTON LJ, 1993, J BONE MINER RES, V8, P1227
[10]
Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass:: Results of the FOSIT study [J].
Pols, HAP ;
Felsenberg, D ;
Hanley, DA ;
Stepán, J ;
Muñoz-Torres, M ;
Wilkin, TJ ;
Qin-sheng, G ;
Galich, AM ;
Vandormael, K ;
Yates, AJ ;
Stych, B .
OSTEOPOROSIS INTERNATIONAL, 1999, 9 (05) :461-468